

Draft - May 9, 2024

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 26-28, 2024

Wednesday, June 26, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30	RSV Vaccines - Adult Introduction Manufacturer presentation: Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years Manufacturer presentation: Arexvy (GSK) immunogenicity with a 24-month revaccination interval Manufacturer presentation: mRNA-1345 (Moderna) season 2 safety and efficacy update; coadministration data Postmarketing safety updates: Vaccine Safety Datalink	Dr. Camille Kotton (ACIP, WG Chair) TBD (Pfizer) TBD (GSK) TBD (Moderna) Dr. James Donahue (Marshfield Clinic Research Institute)
9:45	Break	
9:55	RSV Vaccines - Adult (continued) Observational RSV vaccine effectiveness Economic analysis of adult RSV vaccination Update to benefits and risks discussion Comparison of economic analyses of adult RSV vaccination	Dr. Diya Surie (CDC, NCIRD) Dr. David Hutton (University of Michigan) Dr. David Hutton (University of Michigan) Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
11:15	Break	
11:25	RSV Vaccines - Adult (continued) Evidence to Recommendations Clinical Considerations	TBD (CDC/NCIRD) TBD (CDC/NCIRD)
12:45	Break	
1:30	Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®) Introduction EtR and proposed recommendations: Use of Vaxelis among American Indian and Alaska Native Infants Updated VFC resolution	Dr. Jamie Loehr (ACIP, WG Chair) Dr. Jennifer Collins (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD)
2:30	Break	
2:45	Public Comment	
3:05	VOTES RSV Votes Vaxelis Vaxelis VFC	Dr. Michael Melgar (CDC/NCIRD) Dr. Jennifer Collins (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD)
3:50	Break	
4:00	Chikungunya Vaccine Introduction Update on chikungunya vaccines Epidemiology of chikungunya in U.S. territories and states Cost-effectiveness of use of live attenuated chikungunya vaccine among adults living in U.S. territories Next steps for Work Group	Dr. Wilbur Chen (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Kelly Kilburn, Dr. Erin Staples (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
5:00	Dengue Vaccines	Dr. Joshua Wong (CDC/NCEZID)
5:10	Recess	

Draft - May 9, 2024

Thursday, June 27, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) <i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH</i>
8:15	Agency Updates	
8:35	COVID-19 Vaccine	
	Introduction	Dr. Matt Daley (ACIP, WG Chair)
	COVID-19-associated hospitalizations	Dr. Christopher Taylor (CDC/NCIRD)
	COVID-19 vaccine effectiveness update	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Vaccine safety update for 2023-2024 COVID-19 vaccine	Dr. Jonathan Duffy (CDC/NCEZID)
	Economic analysis of COVID-19 vaccination	Dr. Lisa Prosser (University of Michigan)
	Evidence to recommendations	Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
	COVID-19 vaccine implementation	Dr. Shannon Stokely (CDC/NCIRD)
11:05	Break	
11:20	Influenza Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Influenza A (H5N1) Update	TBD
12:00	Break	
1:00	Influenza Vaccines (continued)	
	WG Considerations and Proposed Recommendations	Dr. Lisa Grohskopf (CDC/NCIRD)
2:00	Pneumococcal Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Economic analysis and public health impact of PCV21 use in adults	Dr. Charles Stoecker (Tulane University)
	Comparison of economic analysis on PCV21 use in adults	Dr. Andrew Leidner (CDC/NCIRD)
	Summary of WG Interpretation of EtR and policy options on PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
	Clinical considerations for PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
3:55	Break	
4:10	Public Comment	
4:30	<u>VOTES</u>	
	COVID-19	Dr. Megan Wallace (CDC/NCIRD)
	Pneumococcal	Dr. Miwako Kobayashi (CDC/NCIRD)
	Influenza	Dr. Lisa Grohskopf (CDC/NCIRD)
5:15	Recess	

Friday, June 28, 2024

8:30	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:55	Meningococcal Vaccines	
	Introduction	Jamie Loehr (ACIP, WG Chair)
	Epidemiology Updates	Ms. Amy Rubis (CDC/NCIRD)
	GSK Pentavalent Vaccine Immunogenicity and Safety	Dr. Wendy Sohn (GSK)
	WG Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination	Dr. Sarah Schillie (CDC/NCIRD)
10:00	Break	
10:15	RSV Vaccines - Maternal/Pediatric	
	Introduction	Dr. Sarah Long (ACIP, WG Chair)
	Implementation and uptake of nirsevimab and maternal RSV vaccine	Dr. Shannon Stokley (CDC/NCIRD)
	Maternal RSV vaccine safety surveillance	Dr. Pedro Moro (CDC/NCEZID)
	Summary of effectiveness of nirsevimab in infants	Dr. Amanda Payne (CDC/NCIRD)
	Work Group considerations	Dr. Jefferson Jones, Dr. Katherine Fleming-Dutra (CDC/NCIRD)
11:40	HPV Vaccines	
	Announcement of formation of an ACIP HPV vaccines work group	Dr. Oliver Brooks (ACIP, WG Chair)
11:50	Adjourn	

Acronyms

CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2

WG Work Group
WHO World Health Organization
VE Vaccine Effectiveness